Australia · Delayed Price · Currency is AUD Oneview Healthcare Earnings Call Transcripts
Fiscal Year 2026
-
Recurring revenue rose 13% (20% constant currency), now 79% of total, with gross margin up to 70%. Cost discipline improved EBITDA loss by 11% and reduced cash outflow by 15%. Bedside Hub and U.S. expansion drive growth, while AI boosts efficiency.
Fiscal Year 2025
-
Revenue grew 21% in 2025, driven by U.S. expansion and new product launches, while gross margin declined to 64% due to revenue mix. Cost efficiencies and AI-driven innovation are expected to support further growth and margin stability in 2026.
-
Revenue grew 36% year-over-year in H1 2025, driven by strong U.S. performance and new deployments, though gross margin declined due to hardware mix. Restructuring and AI innovation position the company for improved efficiency and growth in H2 2025.
Fiscal Year 2024
-
Revenue grew 5% to €9.9M in 2024, with recurring revenue up 9% and gross margin steady at 67%. Eight new US customer logos and expanded Baxter partnership drove record pipeline growth. Deferred revenues from delayed projects are expected in 2025.
-
The AGM highlighted a two-year extension and Canadian expansion of the Baxter partnership, positioning for growth in North America. All 15 resolutions passed with over 99.7% approval, and no shareholder questions were raised during the meeting.
-
First half 2024 saw modest revenue growth (8% recurring, 7% total) and record gross margins, despite project delays from health system consolidation. The Baxter partnership is driving a strong U.S. pipeline, with scalability and AI initiatives set to accelerate growth in H2.